OR WAIT null SECS
April 07, 2022
Several legislative initiatives on table that would extend agency’s reach
March 31, 2022
IP claims under microscope amid arguments over R&D policy and investment.
March 24, 2022
Measures being mulled to reform the AA process and address public concerns around its risk-benefit payoff.
March 22, 2022
Quality metrics, more domestic production aim to avoid supply disruptions and drug shortages.
March 15, 2022
The US Congress approved a federal spending package that increases funding for a range of programs to advance health and medicine.
March 11, 2022
From supply-chain and clinical-trial disruptions in Ukraine and Russia, to decisions to halt investment or maintain operations, global implications for industry and pharmaceutical production are immense.
February 22, 2022
Agency clarifies stance on applications for ‘me-too’ drugs not supported by multiregional trials.
February 16, 2022
Pressurized political, COVID climates greet his return to top spot.
February 08, 2022
Agency restarts more routine site visits amid slowdown of new COVID infections.
February 07, 2022
Political issues delay Senate confirmation of Califf.